ArticleEye (London, England)2024
Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients.
Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema.BMC ophthalmology · 2025Trial
- Homocysteine and mitophagy in diabetic retinopathy: unraveling the underlying molecular crosstalk.Endocrine · 2026Review
- Anti-vascular endothelial growth factor conundrum.Indian journal of ophthalmology · 2026Article
- Real-world outcomes of anti-VEGF and corticosteroid therapies for diabetic macular edema: up to 10 years of follow-up in Korean patients.Japanese journal of ophthalmology · 2026Article
- Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review.Ophthalmology and therapy · 2026Review
- Impact of baseline visual acuity, time-in-range and early treatment on functional outcomes in DMO: insights from the IRISS outcomes.Eye (London, England) · 2026Article
- First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.BMJ open ophthalmology · 2026Article
- Research advances in the translational application of anti-VEGF combined with subthreshold micropulse laser therapy for refractory diabetic macular edema.American journal of translational research · 2026Review
- Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (IluvienOphthalmology and therapy · 2026Article
- Beyond the First Year of Intravitreal Faricimab for Diabetic Macular Oedema: A Single-Centre Experience.Cureus · 2025Article
- Between Scylla and Charybdis?-Health insurance claims-data to monitor quality of service delivery in ophthalmology.Eye (London, England) · 2024Article
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn England and Wales, treatment options were limited for patients with diabetic macular oedema (DMO) with phakic eyes that failed anti-vascular endothelial growth factor (anti-VEGF) treatment pre-2022. This study aimed to quantify the response to, and treatment burden of, anti-VEGF treatment in phakic eyes.
methodsRetrospective, cohort study using electronic patient record data from two UK centres between 2015 and 2020. Primary objective was proportion of phakic eyes with a suboptimal response after initial 6 months of anti-VEGF treatment. Data were available for 500 eyes from 399 patients.
resultsAt 6 months significantly more eyes had a suboptimal response to anti-VEGF treatment: 65.8% (95% CI 61.5-70.0%) vs 34.2% (95% CI 30.0-38.5%), p < 0.0001. Baseline visual acuity (VA) predicted VA outcome, however, despite greater gains in eyes with poorer VA, such eyes did not achieve the same VA levels as those who started treatment with better VA. Only 53.6% of eyes had more than three injections in the first 6 months indicating difficulties in delivering high volume/high frequency treatment. Treatment and review burden were similar over the following years regardless of response to anti-VEGF treatment.
conclusionsData confirm previous real world evidence around response to anti-VEGF treatment, importance of baseline VA and frequency of injections in predicting outcomes in a UK setting. Continuing treatment beyond 6 months in suboptimal responders imposes unnecessary treatment burden without significant change in VA. In suboptimal responders, consideration of early switch to longer acting steroid treatments may help to reduce treatment burden, whilst maintaining or improving vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.